Dexasone LA injection and Lapatinib Ditosylate
Determining the interaction of Dexasone LA injection and Lapatinib Ditosylate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Talk to your doctor before using lapatinib together with dexamethasone. Combining these medications may reduce the blood levels and effects of lapatinib. Contact your doctor if your symptoms worsen or your condition changes during treatment with these medications. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme. In healthy subjects, administration of lapatinib in combination with the CYP450 3A4 inducer carbamazepine (100 mg twice daily for 3 days, then 200 mg twice daily for 14 days) resulted in a 72% reduction of lapatinib systemic exposure (AUC) compared to control.
MANAGEMENT: The use of lapatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided. If concomitant use is unavoidable, the manufacturer recommends titrating the lapatinib dosage gradually from 1250 mg/day up to 4500 mg/day depending on patient tolerability. Based on pharmacokinetic studies, this dosage is predicted to adjust the lapatinib systemic exposure (AUC) to the range observed without inducers. However, clinical data are lacking. The dosage should be reduced to the indicated dosage following discontinuation of the potent CYP450 3A4 inducer. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with lapatinib is unknown.
- "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: dexamethasone
Brand name: De-Sone LA, Dexacen-4, Dexasone, Dexasone LA, Solurex, Solurex LA, Baycadron, Dexamethasone Intensol, DexPak 10 Day Taperpak, DexPak 13 DayTaperpak, DexPak 6 DayTaperpak, Decadron, DexPak, TaperDex, Zema-Pak, ZoDex, Zonacort
Synonyms: Dexasone LA (injection)
Generic Name: lapatinib
Brand name: Tykerb
Synonyms: Lapatinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dexasone LA injection-Lariam
- Dexasone LA injection-Larin 1.5/30
- Dexasone LA injection-Larin 1/20
- Dexasone LA injection-Larin 24 Fe
- Dexasone LA injection-Larin Fe 1.5/30
- Dexasone LA injection-Larin Fe 1/20
- Lapatinib Ditosylate-Dexbrompheniramine
- Lapatinib Ditosylate-Dexbrompheniramine and Acetaminophen Caplets
- Lapatinib Ditosylate-Dexbrompheniramine and phenylephrine
- Lapatinib Ditosylate-Dexbrompheniramine and Phenylephrine Syrup
- Lapatinib Ditosylate-Dexbrompheniramine and Phenylephrine Tablets
- Lapatinib Ditosylate-Dexbrompheniramine and pseudoephedrine